Researchers performed a large, prospective cohort study through the Dutch national CRC screening program. Researchers selected 22,064 screening-naïve individuals and had them do both tests with the same bowel movement. FITs were completed for 21,708 participants. Those participants with positive results underwent a colonoscopy.
Here’s what they found:
1. A total of 2,112 participants had a positive result from one or both of the FITs, and 1,778 underwent a colonoscopy to confirm the diagnosis.
2. FOB-Gold detected advanced neoplasia in 610 participants while OC-Sensor detected advanced neoplasia in 606 participants.
3. Of the 21,078 patients who took both tests, 1,582 had a positive result from FOB-Gold, and 1,627 had a positive result from OC-Sensor.
4. The relative true positive rate was 0.97 for FOB-Gold and 0.95 for OC-Sensor.
Researchers concluded, “In a large, prospective study of individuals invited for CRC screening in The Netherlands, we found no significant difference in the ability of the FOB-Gold FIT versus the OC-Sensor FIT to detect advanced neoplasia. These results are relevant for selecting FITs for CRC screening programs worldwide.”
More articles on gastroenterology:
Supply chain tip of the day: Standardize products
5 must-read articles for GI physicians this week
Orthopedic procedure volume grows in the ASC, outpatient settings: 10 key statistics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.